Using urine tests to reduce checkups for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether monitoring urine tumor DNA can safely reduce how often patients need invasive cystoscopy checkups after initial treatment for non-muscle invasive bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk non-muscle invasive bladder cancer (defined by urology guidelines).
- You completed induction therapy with BCG or gemcitabine/docetaxel.
- Your first checkup after induction therapy showed no cancer (negative cytology and cystoscopy, with or without biopsy).
- You did not have high-risk bladder cancer in the last 3 years.
- You did not receive prior induction intravesical therapy for a previous high-risk cancer.
- You do not have variant histology or cancer in the upper urinary tract.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether urine tests can help monitor “non-muscle-invasive” bladder cancer without doing as many invasive bladder scopes (cystoscopies). If you qualify, you may be able to replace some scope visits with urine sample testing while still keeping close watch for cancer coming back.
This trial tests non-invasive tests (using urine samples and scheduled bladder procedures) to help detect bladder cancer. It may be helpful if you are having bladder evaluation or surgery and your care team wants better ways to detect cancer without invasive testing beyond what you already need.
This trial tests a tiny device placed into bladder tumors before surgery to see which drugs might work best for each patient, helping guide future treatment choices.
This study collects urine samples to test UroAmp, a new genetic test that may help detect and monitor bladder cancer. It is for people with bladder cancer or blood in urine who want to help improve cancer detection.
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
This study tests a urine test that may help find bladder cancer early without needing invasive procedures. It is for people with high-grade or high-risk non-muscle-invasive bladder cancer who are receiving or have received BCG treatment.
Hear when a new Non-muscle Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.